PL4346818T3 - Stałe postacie dawkowania i schematy dawkowania obejmujące (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metoksyfenylo)-4,5-dimetylo-5- (trifluorometylo)tetrahydrofurano-2-karbonylo]amino]pirydyno-2- karboksyamid - Google Patents

Stałe postacie dawkowania i schematy dawkowania obejmujące (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metoksyfenylo)-4,5-dimetylo-5- (trifluorometylo)tetrahydrofurano-2-karbonylo]amino]pirydyno-2- karboksyamid

Info

Publication number
PL4346818T3
PL4346818T3 PL22741050.3T PL22741050T PL4346818T3 PL 4346818 T3 PL4346818 T3 PL 4346818T3 PL 22741050 T PL22741050 T PL 22741050T PL 4346818 T3 PL4346818 T3 PL 4346818T3
Authority
PL
Poland
Prior art keywords
difluoro
carboxamide
trifluoromethyl
carbonyl
pyridine
Prior art date
Application number
PL22741050.3T
Other languages
English (en)
Inventor
Radhika KARKARE
Cathy CHU
Brenda CIRINCIONE
Darin J. CORRELL
Philip Kaj Harder DELFF
Kirk Raymond DINEHART
Paloma BENITO GALLO
Tanya Louise HAY
Licong JIANG
James B. Jones
Katie L. MCCARTY
Catherine P. METZLER
Jonathan M. Miller
Mark C. Peterson
Rahul ROOPWANI
John F. STAROPOLI
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of PL4346818T3 publication Critical patent/PL4346818T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL22741050.3T 2021-06-04 2022-06-03 Stałe postacie dawkowania i schematy dawkowania obejmujące (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metoksyfenylo)-4,5-dimetylo-5- (trifluorometylo)tetrahydrofurano-2-karbonylo]amino]pirydyno-2- karboksyamid PL4346818T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163196937P 2021-06-04 2021-06-04
US202163196933P 2021-06-04 2021-06-04
US202163285201P 2021-12-02 2021-12-02
US202163285197P 2021-12-02 2021-12-02
PCT/US2022/032253 WO2022256708A1 (en) 2021-06-04 2022-06-03 Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide

Publications (1)

Publication Number Publication Date
PL4346818T3 true PL4346818T3 (pl) 2026-03-23

Family

ID=82492526

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22741050.3T PL4346818T3 (pl) 2021-06-04 2022-06-03 Stałe postacie dawkowania i schematy dawkowania obejmujące (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metoksyfenylo)-4,5-dimetylo-5- (trifluorometylo)tetrahydrofurano-2-karbonylo]amino]pirydyno-2- karboksyamid

Country Status (19)

Country Link
US (1) US20240285596A1 (pl)
EP (2) EP4346818B1 (pl)
JP (1) JP2024520649A (pl)
KR (1) KR20240031299A (pl)
AU (1) AU2022284952A1 (pl)
BR (1) BR112023025264A2 (pl)
CA (1) CA3222197A1 (pl)
DK (1) DK4346818T3 (pl)
FI (1) FI4346818T3 (pl)
HR (1) HRP20260068T1 (pl)
IL (1) IL308954A (pl)
LT (1) LT4346818T (pl)
MA (1) MA64856B1 (pl)
MX (1) MX2023014376A (pl)
PL (1) PL4346818T3 (pl)
PT (1) PT4346818T (pl)
SM (1) SMT202600064T1 (pl)
TW (1) TW202317108A (pl)
WO (1) WO2022256708A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202516632A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
JP2026503260A (ja) * 2023-01-06 2026-01-28 ハイスーク ファーマシューティカル グループ カンパニー リミテッド テトラヒドロチオフェン誘導体及びその医薬的な応用
US20250186419A1 (en) * 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
CN120058684A (zh) * 2024-02-23 2025-05-30 山东盛迪医药有限公司 一种取代四氢呋喃化合物的结晶形式及其制备方法
CN120058686A (zh) * 2024-02-23 2025-05-30 山东盛迪医药有限公司 一种取代四氢呋喃化合物的可药用盐、其结晶形式及用途
CN117838648B (zh) * 2024-03-05 2024-05-28 瑞阳制药股份有限公司 Suzetrigine片剂及其制备方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026012382A1 (zh) * 2024-07-10 2026-01-15 海思科医药集团股份有限公司 一种硫杂环戊基衍生物的药物制剂及其在医药上的应用
CN119143737B (zh) * 2024-11-18 2025-07-18 嘉兴安帝康生物科技有限公司 四氢呋喃甲酰胺类钠通道调节剂及其在医药上的应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
MXJL03000001A (es) 2000-07-10 2004-02-09 Vertex Pharma San Diego Llc Metodos de ensayo de canales de iones.
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6492618B1 (en) 2000-11-02 2002-12-10 Tri Tool Inc. Automatic weld head alignment and guidance system and method
MX2007000885A (es) 2004-07-23 2007-03-12 Pfizer Derivados de piridina.
CN103271906A (zh) 2006-10-12 2013-09-04 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
WO2008135826A2 (en) 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
CN102264707B (zh) 2008-12-26 2014-09-03 大日本住友制药株式会社 双环型杂环化合物
US9174999B2 (en) 2009-05-07 2015-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
HUE028789T2 (en) 2011-02-02 2017-01-30 Vertex Pharma Pyrrolopyrazine spirocyclic piperidinamides as modulators of ion channels
CN103443105A (zh) 2011-02-18 2013-12-11 沃泰克斯药物股份有限公司 作为离子通道调节剂的苯并二氢吡喃-螺环哌啶酰胺
WO2012116440A1 (en) 2011-03-03 2012-09-07 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
EA023375B1 (ru) 2011-10-26 2016-05-31 Пфайзер Лимитед Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
EP2788332A1 (en) 2011-12-07 2014-10-15 Amgen, Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
CA2863343A1 (en) 2012-01-16 2013-07-25 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
CA2861439C (en) 2012-02-03 2016-07-12 Pfizer Inc. Benzimidazole and imidazopyridine derivatives as sodium channel modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
GEP20207177B (en) 2013-01-31 2020-11-10 Parmaceuticals Incorporated Vertex Pyridone amides as modulators of sodium channels
CA2898653C (en) 2013-01-31 2021-09-28 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
RU2683788C2 (ru) 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов
WO2014201173A1 (en) 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GEP20207102B (en) 2013-07-19 2020-05-11 Vertex Pharma Sulfonamides as modulators of sodium channels
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
US10106549B2 (en) 2014-04-09 2018-10-23 Siteone Therapeutics, Inc. 10′,11′-modified saxitoxins useful for the treatment of pain
WO2016141035A1 (en) 2015-03-02 2016-09-09 Amgen Inc. Bicyclic ketone sulfonamide compounds
ES2895155T3 (es) 2015-09-30 2022-02-17 Siteone Therapeutics Inc Saxitoxinas modificadas en 11,13 para el tratamiento del dolor
MX2019011530A (es) 2017-03-29 2020-01-27 Siteone Therapeutics Inc Saxitoxinas 11,13-modificadas para el tratamiento del dolor.
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
JP7104070B2 (ja) 2017-05-16 2022-07-20 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての重水素化ピリドンアミドおよびそのプロドラッグ
BR112020000553A2 (pt) 2017-07-11 2020-07-21 Vertex Pharmaceuticals Incorporated carboxamidas como moduladores de canal de sódio
SG11202001129VA (en) * 2017-08-11 2020-03-30 Merck Patent Gmbh Pharmaceutical preparation comprising 3-fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1 h-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl]-benzonitrile
US11993581B2 (en) 2018-07-09 2024-05-28 Lieber Institue, Inc Pyridazine compounds for inhibiting Nav1.8
JP2021530478A (ja) 2018-07-09 2021-11-11 リーバー インスティチュート インコーポレイテッドLieber Institute, Inc. ＮａＶ１．８を阻害するためのピリジンカルボキシアミド化合物
WO2020072835A1 (en) 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
EP3873468A4 (en) 2018-11-02 2022-10-26 Merck Sharp & Dohme LLC 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS
MX2021005154A (es) 2018-11-02 2021-07-15 Merck Sharp & Dohme Llc 2- amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8.
KR20210112336A (ko) 2019-01-04 2021-09-14 지앙수 헨그루이 메디슨 컴퍼니 리미티드 6-옥소-1,6-디하이드로피리다진 유도체, 이의 제조 방법, 및 이의 의약적 용도
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
TW202043200A (zh) 2019-01-25 2020-12-01 大陸商江蘇恆瑞醫藥股份有限公司 ２－側氧基－１，２－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
CN114040911B (zh) 2019-06-27 2024-10-22 葛兰素史密斯克莱知识产权发展有限公司 作为nav1.8抑制剂的2,3-二氢喹唑啉化合物
CN112300051A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN112300069A (zh) 2019-07-31 2021-02-02 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
WO2021032074A1 (zh) 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CN112390745B (zh) 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
CN112441969A (zh) 2019-08-30 2021-03-05 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN113906013B (zh) 2019-09-12 2024-03-12 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
EP4069691B1 (en) 2019-12-06 2024-09-18 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
CN111217776A (zh) 2020-01-19 2020-06-02 中国人民解放军军事科学院军事医学研究院 含苯并杂环结构的酰胺衍生物、组合物和应用
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
EP4595965A3 (en) 2020-06-10 2025-08-13 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
MX2022015580A (es) 2020-06-17 2023-01-24 Merck Sharp & Dohme Llc 5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8.
GEAP202416135A (en) 2020-06-17 2024-10-10 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
AU2021292061A1 (en) 2020-06-17 2023-01-19 Merck Sharp & Dohme Llc 2-oxo-oxazolidine-5-carboxamides as Nav1.8 inhibitors
IL300626A (en) 2020-08-14 2023-04-01 Siteone Therapeutics Inc Ketone-free inhibitors of NAV1.7 for the treatment of pain
TW202214259A (zh) 2020-08-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種選擇性ＮａＶ抑制劑的前藥及其晶型
WO2022037647A1 (zh) 2020-08-19 2022-02-24 江苏恒瑞医药股份有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
CN111808019B (zh) 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN112225695B (zh) 2020-12-15 2021-03-02 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
CN112457294B (zh) 2021-01-27 2021-06-04 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途

Also Published As

Publication number Publication date
JP2024520649A (ja) 2024-05-24
AU2022284952A1 (en) 2023-12-14
CA3222197A1 (en) 2022-12-08
LT4346818T (lt) 2026-03-25
MA64856B1 (fr) 2026-02-27
WO2022256708A1 (en) 2022-12-08
IL308954A (en) 2024-01-01
TW202317108A (zh) 2023-05-01
MX2023014376A (es) 2024-03-04
SMT202600064T1 (it) 2026-03-09
EP4714435A2 (en) 2026-03-25
PT4346818T (pt) 2026-02-17
HRP20260068T1 (hr) 2026-02-27
BR112023025264A2 (pt) 2024-02-20
DK4346818T3 (da) 2026-02-02
FI4346818T3 (fi) 2026-02-05
KR20240031299A (ko) 2024-03-07
US20240285596A1 (en) 2024-08-29
EP4346818A1 (en) 2024-04-10
EP4346818B1 (en) 2025-12-03

Similar Documents

Publication Publication Date Title
LT4346818T (lt) Kietos formos ir dozavimo režimai, apimantys (2r,3s,4s,5r)-4-[[3-(3,4- difluor-2-metoksi-fenil)-4,5-dimetil-5-(trifluormetil) tetrahidrofuran-2- karbonil]amino]piridin-2-karboksamidą
LU92172I2 (fr) Solvat acétonique du cabazitaxel, ou désigné solvat acétonique du diméthoxy docetaxel ou solvat acétonique du (2R,3S)-3-tertbutoxycarbonylamino-2-hydroxy-3-phénylpropionate de 4-acetoxy-2a-benzoyloxy-5ß,20-époxy-1-hydroxy-7ß,10a-diméthoxy-9-oxo-tax-11-ène-13a-yle (acétonate du cabazitaxel)
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
SE0003449L (sv) Cancerhämmande kompositioner
EA200401252A1 (ru) Микрочастицы лекарственных веществ
IL174301A0 (en) Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes
ATE490264T1 (de) Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen
MXPA03009971A (es) FORMA DE DOSIFICACIoN FARMACEUTICA DE MESILATO DE NELFINAVIR AMORFO.
IL290871A (en) Pharmaceutical formulations and dosage regimens for multi-binding proteins that bind her2, nkg2d, and cd16 for cancer therapy
EA200970396A1 (ru) Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность
HK40109212A (en) Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
Fenichel et al. Combination products as first-line pharmacotherapy
EP4324841A4 (en) Cell-penetrating peptide, anticancer peptide and pharmaceutical composition for preventing or treating cancer therewith
EP4180446A4 (en) CYCLIC PEPTIDE, PEPTIDE COMPLEX AND MEDICINAL COMPOSITION CONTAINING THE CYCLIC PEPTIDE AND/OR THE PEPTIDE COMPLEX
FR2865208B1 (fr) Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
WO2003061571A3 (en) Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
ATE360420T1 (de) VERWENDUNG VON WIRKSTOFFEN MIT µ-OPIOID-REZEPTOR AGONISTISCHER WIRKUNG UND OPIOID-REZEPTOR ANTAGONISTISCHER WIRKUNG ALS KOMBINATIONSARZNEIMITTEL ZUR KREBSBEHANDLUNG
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
AU2024248738A1 (en) Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CA3287413A1 (en) Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
EP1854798A3 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2006121857A3 (en) Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses
CA3279434A1 (en) Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same
HK40128851A (en) Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same
EP4617265A4 (en) SPIROCYCLIC COMPOUND CONTAINING NITROGEN, PHARMACEUTICAL COMPOSITION AND USE THEREOF